ScholarLens Back to search
2008•European Journal of Cancer SupplementsRequires access

Bevacizumab in the first-line treatment of metastatic breast cancer

David Cameron

Open publisher page 13 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Bevacizumab, Medicine, Internal medicine, Paclitaxel, Metastatic breast cancer, Taxane, Oncology, Neutropenia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Bevacizumab in the first-line treatment of metastatic breast cancer — Research Paper | ScholarLens